The Cares Approach to Patient-Centered Diabetes Management: One Size No Longer Fits All

REGISTER NOW!
Already Registered?
SIGN IN

WEBCAST DATE

Saturday, August 17, 2019

8:00 AM Eastern    7:00 AM Central    6:00 AM Mountain    5:00 AM Pacific

PROGRAM FEATURES

• Create your own Personalized Poster
• Interactive, case-based learning environment
• iPads provided to enhance learning experience
• VIRTUAL REALITY SETS provided to all attendees for viewing this presentation only

FACULTY

Silvio Inzucchi, MD, Program Chair
Internal Medicine
Diabetes Research Center, Endocrinology Diabetes Center, Pituitary Program
Yale Cancer Center, Endocrine Cancers Program Yale Medicine
New Haven, CT

Richard Pratley, MD
Associate Medical Director of Research and Education
AdventHealth Diabetes Institute Orlando, FL

AGENDA

  I. Diabetes overview
    A. Epidemiology
    B. Glycemic control status in population
      • Factors associated with poor glycemic control

  II. Patient-centered diabetes management
    A. Non-glycemic factors associated with diabetes
      • Comorbidities
      • Psychosocial
    B. Communication strategies
      • Patient-centered language
      • Techniques for facilitating adherence

  III. Patient-centered approach to treatment initiation/intensification
    A. ADA standards of care/AACE glycemic control algorithm
      • Considerations for patients with renal disease or heart failure
    B. Lifestyle modification
    C. Overcoming psychosocial barriers
    D. Pharmacotherapy initiation
    E. Treatment intensification
      • Overcoming clinical inertia
      • Balancing between optimal glucose control and hypoglycemia
    F. Individualized glycemic goals
      • ADA – general recommendations
      • AACE – glycemic control algorithm
      • Extraglycemic effects and patient outcomes

  IV. Anti-hyperglycemic, cardiovascular and renal effects of agents used in T2DM
    A. Oral therapies
      • Metformin, sulfonylureas, thiazolidinediones (TZD), dipeptidyl peptidase 4 (DPP-4) inhibitors, sodium-glucose co-transporter-2 (SGLT-2) inhibitors
    B. Injectable therapies
      • Insulin
        - Novel formulations
      • Glucagon like peptide-1 (GLP-1) agonists
        - Potential cardiovascular impact
    C. Combination therapy
    D. Future of T2DM management

  V. Conclusion
    • Moving forward
    • Q&A

LEARNING OBJECTIVES

After completing the educational activity, learners should be better able to:

• Describe how a patient-centered approach to the care of patients with T2DM can help improve glycemic control,reduce complications and improve patient self- management
• Assess strategies for the use of various oral and injectable medications for treatment intensification in patients with T2DM not meeting their glycemic goals
• Review updated guidelines and algorithms pertinent to the management of patients with T2DM, with or without concomitant heart failure or renal disease
• Evaluate the role of SGLT2 inhibitors and GLP-1 receptor agonists in managing cardiovascular and renal risk in patients with T2DM

TARGET AUDIENCE

This educational activity is intended for endocrinologists, cardiologists, nephrologists, primary care physicians, physician assistants, nurse practitioners, pharmacists, certified diabetes educators and other clinicians who care for patients with diabetes.

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 2.0 AMA Category 1 Credit(s)^TM.
 
Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with Diabetes.

CNE Credits: 2.0 ANCC Contact Hour(s)

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 2.0 contact hour(s) of continuing nursing education of RNs and APNs.

AOA ACCREDITATION STATEMENT

The American Osteopathic Association (AOA) Council on Continuing Medical Education has approved this activity for 2 AOA Category 2-A credits.

ACPE ACCREDITATION STATEMENT

Amedco is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Successful completion of this program qualifies for up to 2 contact hours. Full attendance is required. No partial contact hours will be awarded for partial attendance.UAN#TBD

DIETICIAN ACCREDITATION STATEMENT

This program has received prior approval with the Commission on Dietetic Registration for dieticians and RDs

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Med Learning Group prior to the live event at info@medlearninggroup.com

Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.